2025年中国创新药进入厚积薄发时期,近期更是多点开花:阿斯利康与石药集团达成总额53亿美元的战略合作;三生制药与辉瑞就抗肿瘤药物SSCJ-707达成交易,辉瑞将支付12.5亿美元首付款、最高48亿美元里程碑付款;百时美施贵宝拿下德国BioNTech的PD-L1/VEGF双抗BNT327,潜在交易总额有望达到111亿美元。而BNT327是BioNTech以不到21亿美元的价格从中国创新药企普米斯...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.